Evidence map›Paper›PMID 35337165›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Enantioselectivity of Pentedrone and Methylone on Metabolic Profiling in 2D and 3D Human Hepatocyte-like Cells.

Bárbara Silva, Joana Saraiva Rodrigues, Ana Sofia Almeida, Ana Rita Lima, Carla Fernandes, Paula Guedes de Pinho, Joana Paiva Miranda, Fernando Remião

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bárbara SilvaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0001-7399-0197
Joana Saraiva RodriguesResearch Institute for Medicines (imed), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0002-1772-9813
Ana Sofia AlmeidaLaboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0001-6826-1854
Ana Rita LimaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0003-1439-770X
Carla FernandesLaboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0003-0940-9163
Paula Guedes de PinhoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0002-7395-5700
Joana Paiva MirandaResearch Institute for Medicines (imed), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal.ORCID 0000-0002-7804-4068
Fernando RemiãoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.ORCID 0000-0003-1382-5119
Universidade do Porto · PTUniversity of Lisbon · PT

Funding

Erasmus+ Programme of the European Union Project no. 2020-1-CZ01-KA203-078218FCT PTDC/MED-TOX/29183/2017, SFRH/BD/144130/2019FCT UIDB/04138/2020 e UIDP/04138/2020FCT UIDB/04378/2020FCT UIDB/04423/2020 and UIDP/04423/2020University of Porto/ Faculty of Medicine University of Porto through FSE-Fundo Social Europeu, NORTE2020-Programa Operacional Regional do Norte NORTE-08-5369-FSE-000011
6 · The paper itself

Abstract

Pentedrone and methylone can express stereoselectivity in toxicokinetic and toxicodynamic processes. Similarly, their chiral discrimination in metabolism, which was not yet evaluated, can result in different metabolic profiles and subsequent hepatotoxic effects. Therefore, the aim of this work was to assess, for the first time, both the hepatic cytotoxic and metabolic profile of pentedrone and methylone enantiomers using physiologically relevant in vitro models. The hepatotoxicity of these compounds was observed in a concentration-dependent manner in human stem-cell-derived hepatocyte-like cells (HLCs) cultured under 3D (3D-HLCs) and 2D (2D-HLCs) conditions. Enantioselectivity, on the other hand, was only shown for pentedrone (1 mM) in 3D-HLCs, being

Indexed as

3D-HLCscathinoneschiralityenantiomerslivermetabolism

Identifiers

PMID35337165
PMCPMC8953427
OpenAlexW4220770158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.